Compound Profiles
CJC/IPA Protocol
GHRH/GHRP Combination | Growth Hormone Optimization
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Tesamorelin
GHRH Analog | Visceral Fat Reduction
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC/IPA Protocol with Tesamorelin?
Yes, but with caution. Both CJC/IPA Protocol and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.
Is CJC/IPA Protocol and Tesamorelin safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting. Monitor accordingly.
What are the interactions between CJC/IPA Protocol and Tesamorelin?
Both CJC/IPA Protocol and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.